A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 458-461

  Eron, Joseph J ^a   Haubrich, Richard ^b   Lang, William ^c   Pagano, Grace ^d   Millard, Judith ^d   Wolfram, Josie ^f   Snowden, Wendy ^e   Pedneault, Louise ^d   Tisdale, Margaret ^f  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ViRx Inc   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Univ of N Carolina at Chapel Hill ^*

Author keywords

Amprenavir; Dual protease inhibitor therapy; Indinavir; Nelfinavir; Saquinavir

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035870551     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200104150-00008     Document Type: Article

References (13)

1. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-24.
2. Kravcik S, Victor G, Angel JB, et al. Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy (abstract). Clin Infect Dis 1999;29:702-3.
3. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://www.hivatis.org/trtgdlns.html. Accessed January 2000.
4. Murphy R, Gulick R, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis 1999;179:808-16.
5. Pedneault L, Fetter A, Hanson C, et al. Amprenavir (141W94, APV): review of overall safety profile [abstract 386]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, January 31-February 4, U.S.A., 1999.
6. Tisdale M, Myers R, Randall S, et al. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies - a review. Clin Invest Drugs 2000;20:267-85.
7. Tisdale M, Myers R, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39:1704-10.
8. Kellam P, Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994; 38:23-30.
9. Sadler BM, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract 12389]. Presented at the XII World Conference on AIDS, Geneva, Switzerland, June 28-July 3, 1998.
10. De Pasquale MP, Murphy R, Kuritzkes D, et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347 [abstract 71). Presented at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27, 1998.
11. Havlir D, Hellman N, Petropoulos C, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-34.
12. Stein DS, Sadler B, Sale M. Pharmacodynamic effects of amprenavir (APV) + ritonavir (RTV) on different viral populations [abstract 5.2]. Presented at the 1st International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, March 30-April 2, 2000.
13. Baker CT, Chauturvedi PR, Hale MR, et al. Discovery of VX-175/GW433908, a novel, water soluble prodrug of amprenavir [abstract 916]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, U.S.A., September 26-29, 1999.